Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)99.25
  • Today's Change-0.80 / -0.80%
  • Shares traded2.00m
  • 1 Year change-15.89%
  • Beta1.3695
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

  • Revenue in USD (TTM)4.34bn
  • Net income in USD-965.00m
  • Incorporated2000
  • Employees8.97k
  • Location
    Illumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
  • Phone+1 (858) 202-4500
  • Fax+1 (858) 202-4766
  • Websitehttps://www.illumina.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ILMN:NSQ since
announced
Transaction
value
Somalogic IncAnnounced23 Jun 202523 Jun 2025Announced9.68%425.00m
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Henry Schein Inc12.67bn407.00m9.18bn25.00k22.822.7113.170.72443.223.22100.1227.081.234.917.86506,760.003.885.436.389.1931.6030.233.163.980.75256.940.37990.002.714.88-6.25-11.0619.66--
Penumbra Inc1.24bn42.23m9.21bn4.50k231.947.59145.277.431.031.0331.3831.350.78161.026.89275,577.802.661.422.951.5866.3763.213.411.963.68--0.0190.0012.8616.89-84.59-21.98-0.853--
Avantor Inc6.69bn715.60m9.25bn13.50k12.941.528.251.381.051.059.808.950.53295.696.01495,200.005.703.946.624.4833.5633.7610.706.870.75323.950.40240.00-2.642.35121.58--23.59--
Revvity Inc2.77bn296.04m11.96bn11.00k41.921.5916.774.322.422.3522.7063.960.21483.054.59251,806.202.304.312.494.8456.2558.5010.6915.782.9914.590.29326.520.162-0.908657.704.201.274.56
Solventum Corp8.31bn379.00m12.77bn22.00k33.923.9113.831.542.182.1847.6918.850.56834.267.74377,636.402.59--3.05--54.71--4.55--0.85231.930.7081--0.6954---64.41------
Hologic Inc4.03bn556.70m14.65bn7.06k27.753.1717.153.642.372.3717.3120.730.46662.576.24570,083.606.4513.127.2715.2056.4460.8213.8324.752.52110.530.3540.00-0.00253.6673.14--4.30--
Align Technology Inc3.98bn409.56m14.66bn20.95k36.823.8926.153.685.495.4953.4151.940.64954.553.96190,061.706.6813.909.9420.5069.9271.2410.2920.951.08--0.000.003.5410.69-5.32-0.9865-5.04--
Baxter International Inc10.77bn-277.00m14.73bn38.00k--2.0820.891.37-0.5388-1.1021.0313.800.43882.645.04283,447.40-1.09-0.8441-1.37-1.0336.7338.63-2.49-2.031.403.650.5882--2.66-1.31-293.68---8.524.12
Cooper Companies Inc3.99bn414.20m14.92bn16.00k36.251.8019.183.742.062.0619.8641.540.32611.585.43249,262.503.398.723.689.7367.2065.7010.3926.351.236.800.23780.2828.417.9833.34-3.177.59--
Illumina Inc4.34bn-965.00m15.71bn8.97k--6.66--3.62-6.10-6.1027.2314.890.53472.606.36483,500.60-11.90-10.33-14.50-12.1566.3465.65-22.25-25.301.4817.300.4566---2.934.29-5.34---9.34--
West Pharmaceutical Services Inc2.90bn467.20m16.32bn10.60k35.696.0826.625.646.376.3739.4737.370.80214.635.30273,188.7012.5615.6115.0018.7034.5438.0015.6618.842.03--0.071610.20-1.929.48-16.9715.3124.435.84
Zimmer Biomet Holdings Inc7.70bn913.40m18.56bn17.00k20.791.509.632.414.514.5138.0662.630.35290.96225.17452,852.904.192.344.752.6871.0571.1811.887.601.466.460.366537.523.85-0.7725-11.742.05-3.690.00
Insulet Corp2.20bn402.20m20.36bn3.90k52.0615.3041.909.265.565.5629.7218.910.71611.496.08563,820.5013.106.0015.507.0370.3967.0518.299.223.6349.390.56030.0022.0722.92102.76104.84-4.75--
Waters Corp2.98bn657.02m21.00bn7.60k32.0310.7024.687.0411.0211.0250.0432.980.65562.314.45392,533.3014.4418.4118.0223.4659.2758.7122.0222.811.2813.770.4260.000.06674.22-0.68511.61-2.75--
Data as of Jul 11 2025. Currency figures normalised to Illumina Inc's reporting currency: US Dollar USD

Institutional shareholders

47.51%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Mar 202518.90m11.93%
The Vanguard Group, Inc.as of 31 Mar 202515.96m10.08%
BlackRock Fund Advisorsas of 31 Mar 202514.01m8.85%
SSgA Funds Management, Inc.as of 31 Mar 20255.85m3.69%
WCM Investment Management LLCas of 31 Mar 20254.18m2.64%
Loomis, Sayles & Co. LPas of 31 Mar 20254.15m2.62%
Corvex Management LPas of 31 Mar 20253.83m2.42%
Baillie Gifford & Co.as of 31 Mar 20253.01m1.90%
Geode Capital Management LLCas of 31 Mar 20252.85m1.80%
PointState Capital LPas of 31 Mar 20252.52m1.59%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.